Boehringer Ingelheim Gubra to develop anti-obesity peptide poly agonists
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat...
Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies
Lantheus Holdings has collaborated with NanoMab Technology to provide a novel biomarker for clinical development and management of immuno-oncology therapies....
LYNPARZA delivers 72per ORR in phase 3 SOLO3 trial in advanced ovarian cancer
AstraZeneca and Merck presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the...
Vertex Pharmaceuticals to buy US firm Exonics Therapeutics
Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m). Under...
ProtoKinetix achieves primary objective safety at midpoint of clinical trial
ProtoKinetix, announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction...
Janssen partners with nference for AI-based drug development
nference, a leader in knowledge synthesis software solutions for the life sciences industry announced a multi-year alliance with Janssen Research...
AstraZeneca s Calquence shows superiority to chemotherapy in CLL
AstraZeneca has announced Calquence (acalabrutinib) reached both its primary and secondary endpoints in chronic lymphocytic leukaemia (CLL). In preliminary analysis...
Camargo to Acquire Montreal-based InSymbiosis
Camargo Pharmaceutical Services announced it will acquire InSymbiosis, a Canadian drug development partner which improves how biopharma companies outsource R&D....
Samsung BioLogics Enters New Era with First-of-its-kind Client-Centric CMO Deal
Samsung BioLogics (SBL) recently entered a new era by signing a "first of its kind" deal with a US bio-pharmaceutical...
Dr Reddys Laboratories to sell neurology branded products to Upsher-Smith Laboratories
Under the agreement, Dr.Reddy’swill receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations...
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.